Introduction
============

Hepatocellular carcinoma (HCC) is the main type of primary liver cancer, accounting for about 70%--90% of primary liver cancers. HCC is considered as the second leading cause of cancer-related death in men.[@b1-ott-11-909] Despite the fact that there are various therapies for HCC, such as surgical resection, portal vein embolization, percutaneous local ablation, transarterial embolization and chemoembolization, and liver transplantation,[@b2-ott-11-909],[@b3-ott-11-909] its prognosis is still not optimistic. It has been reported that the 5-year survival rate of HCC is only 11%.[@b4-ott-11-909] One of the most crucial causes of the gloomy prognosis of HCC is the lack of effective early diagnostic tools. Most patients are diagnosed at an advanced stage and cannot undergo radical surgery. Therefore, it is of great significance to find efficient biological markers with diagnostic values for the early diagnosis and prognosis of HCC.

Tumor suppressor candidate 3 (*TUSC3*), originally termed as N33, is inspected as a candidate tumor suppressor gene and is located on the human chromosomal band 8p22.[@b5-ott-11-909] It is considered to be related to autosomal recessive mental retardation.[@b6-ott-11-909]--[@b8-ott-11-909] In recent years, studies have shown that *TUSC3* is closely associated with the occurrence, development and invasion of various malignant tumors such as prostate cancer,[@b9-ott-11-909] ovarian cancer,[@b10-ott-11-909]--[@b12-ott-11-909] lung cancer[@b13-ott-11-909]--[@b16-ott-11-909] and colorectal cancer.[@b17-ott-11-909] However, the mechanisms of *TUSC3* in malignant tumors largely remain unclear and the role of *TUSC3* in different tumors is not the same. Few studies have focused on the relationship between *TUSC3* and HCC. In view of the lack of sufficient research in this field, our study examined the expression of *TUSC3* in HCC tissues and the corresponding para-cancerous tissues from 92 samples of HCC patients by immunohistochemistry analysis. Moreover, quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays were applied to detect the mRNA and protein expression of *TUSC3* in 25 paired HCC and adjacent non-tumor tissues. Finally, we analyzed the relationship between the expression of *TUSC3* and clinicopathological features and prognosis of HCC patients.

Materials and methods
=====================

Patients and tissue specimens
-----------------------------

A total of 92 paraffin samples of HCC patients resected from the Department of Liver Surgery, Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, China, from January 2007 to December 2012 were collected for immunohistochemistry analysis. In addition, snap-frozen HCC tissues and the corresponding para-cancerous tissues which were at least 2 cm away from the edge of the tumor from 25 HCC patients with radical HCC resection in Affiliated Anhui Provincial Hospital of Anhui Medical University were obtained for the detection of *TUSC3* expression level by qRT-PCR and Western blot assays. All the clinicopathological data such as age, gender, tumor size, vascular invasion (macroscopic or microscopic tumor thrombus of HCC), tumor Edmondson grade, Barcelona Clinic Liver Cancer (BCLC) stage, tumor capsule, serum alpha fetoprotein (sAFP), hepatitis B surface antigen (HBsAg), cirrhosis, Child-Pugh grade and the number of tumors were gathered retrospectively in the medical record room of the hospital. Details of the patients are shown in [Table 1](#t1-ott-11-909){ref-type="table"}. All the specimens were confirmed to be HCC by postoperative pathological examination and all the patients were not treated with radiotherapy, chemotherapy and interventional therapy before operation. The degree of tumor differentiation was determined by Edmondson classification system[@b18-ott-11-909] and the nineteenth reference of the BCLC stage criteria.[@b19-ott-11-909] The study was followed up for 2--100 months with a median follow-up of 25 months. In addition, the OS time was defined as the time between the date of operation and the date of death or the deadline of follow-up. The disease-free survival (DFS) time was defined as the interval between the date of operation and the date of tumor recurrence which was clearly diagnosed for the first time or the deadline of follow-up. Our study obtained the written informed consent of all patients and the approval of the ethics committee of the clinical laboratory of the Affiliated Anhui Provincial Hospital of Anhui Medical University.

Immunohistochemistry
--------------------

The paraffin-embedded specimens were sliced into 4 µm thick sections, and the pathological sections were placed in a tissue-drying oven at 60°C for 60 minutes. Then, sections were deparaffinized with xylene and were rehydrated through graded ethanol. Next, slides were steamed in 0.01 M sodium citrate buffer (pH 6.0) at 100°C for 20 minutes, and then were removed from heat and cooled down at room temperature in buffer solution for the sake of antigen retrieval. Sections were incubated with 0.3% hydrogen peroxide to block the activity of endogenous peroxidase for 10 minutes. Tissue slides were incubated at 4°C overnight with rabbit anti-human *TUSC3* polyclonal antibody (catalog ID: LS-B13274/68872; LSBio, Seattle, Washington, DC, USA) at a dilution of 1:200, then washed with phosphate-buffered saline (PBS) and incubated with a horseradish peroxidase-conjugated secondary antibody (Zhongshan Golden Bridge Biotechnology, Beijing, China) for 30 minutes. The sections were stained with 3, 3′-diaminobenzidine, counterstained with hematoxylin, dehydrated in grade alcohols and sealed with neutral gum. Immunoreactivity for the expression of *TUSC3* was independently assessed by two professional pathologists from the Affiliated Anhui Provincial Hospital of Anhui Medical University. We used a previously published method[@b15-ott-11-909] to appraise the semi-quantitative expression of *TUSC3* with the following formula: the immunoreactivity score = the staining intensity score × the proportion of positive cells score. The staining intensity score was defined as 0 points (negative), 1 point (weak intensity), 2 points (moderate intensity) and 3 points (strong intensity). The proportion of positive cells score was defined as 0 points (no staining), 1 point (\<25%), 2 points (25%--50%), 3 points (50%--75%) and 4 points (\>75%). The immunoreactivity scores of the sections which were greater than or equal to 6 points were defined as high expression, otherwise were defined as low expression.

Western blot analysis
---------------------

Snap-frozen tumor tissues and the corresponding para-carcinomatous tissues were lysed with RIPA buffer (Beyotime Institute of Biotechnology, Shanghai, China) supplemented with protease inhibitor cocktail. The proteins were quantified with bicinchoninic acid protein assay. Equal amounts of the tumor and the corresponding para-carcinomatous specimen proteins were separated by 8% SDS-PAGE and transferred to the polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). The rabbit anti-human *TUSC3* polyclonal antibody (1:500, catalog ID: LS-B13274/68872; LSBio) and β-actin (1:5,000, 66009-1-Ig; Abmart, Arlington, USA) were used to incubate the membranes at 4°C on a shaking table for overnight after blocking with 5% non-fat milk. Next, the membranes were incubated at room temperature with the corresponding secondary antibodies for 2 hours. Signaling was detected by Alpha-EaseFC imaging system (Alpha Innotech, San Leandro, CA, USA). Using the Alpha-EaseFC software, the integrated density value (IDV) of each band was estimated by describing a rectangle outlining the band. Human antibody of β-actin was used as the control, and the ratio of the IDV of *TUSC3* to the IDV of β-actin was used for statistical analysis.

qRT-PCR analysis
----------------

Total RNA of the 25 pairs of snap-frozen tumors and the corresponding para-carcinomatous tissues was extracted by TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol, and cDNA was synthesized with the Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientifc). The mRNA level of *TUSC3* was detected by SYBR Green-based RT-PCR with a Piko-Real RT-PCR system (Thermo Fisher Scientifc). The PCR amplification was performed according to the following procedure: predenaturation at 94°C for 30 seconds, denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds and finally elongation at 72°C for 30 seconds; a total of 40 cycles were performed. We projected specific primers for *TUSC3* (Primer Designing Tool, NCBI, Bethesda, MD, USA) as follows: forward: 5′-GAGTTCCAGACGCTCAATCTTC-3′ and reverse: 5′-GCCAGGAGTTCGCCAGTATT-3′. The 18S RNA was used as the internalized control gene, and the sequences used were as follows: forward: 5′-CGGCGACGACCCATTCGAAC-3′ and reverse: 5′-GAATCGAACCCTGATTCCCCGTC-3′. We applied melting-curve analysis to control the purity of PCR products. Each experiment was performed three times with three replicates at each time. The relative expression of *TUSC3* mRNA was calculated by 2^−ΔΔCt^ method.

Statistical analysis
--------------------

SPSS 22.0 software (SPSS Inc, Chicago, IL, USA) and Graph Prism 5.0 software (GraphPad Prism, San Diego, CA, USA) were employed in analyzing the data. Quantitative data involved in this study were expressed as mean ± standard deviation, and the independent Student's *t*-test was used for statistical analysis. Chi-square test was performed for qualitative data. The survival curve was drawn by the Kaplan--Meier method, and log-rank test was applied to compare the differences between the survival rates. Cox proportional hazards model was performed for univariate and multivariate analyses of prognostic outcomes. *P*\<0.05 was considered to be statistically significant.

Results
=======

The expression of *TUSC3* was downregulated in HCC tissues
----------------------------------------------------------

To investigate the expression of *TUSC3* in HCC patients, we performed immunohistochemistry analysis to analyze the *TUSC3* expression in a retrospective cohort including 92 clinicopathologically characterized HCC patients. Results of immunohistochemistry showed that low expression of *TUSC3* was found in 56 (60.9%) HCC tissues and 33 (35.9%) para-cancerous liver tissues, and the difference was statistically significant (*χ*^2^=11.512, *P*\<0.05). The positive expression of *TUSC3* was mainly observed in the cytoplasm of HCC and para-cancerous liver tissues ([Figure 1](#f1-ott-11-909){ref-type="fig"}). Western blot analysis demonstrated that in 19 of the 25 paired tissues (76%), the protein expression of *TUSC3* was obviously lower in HCC tissue than the corresponding para-cancerous liver tissues. As shown in [Figure 2](#f2-ott-11-909){ref-type="fig"}, the relative protein expression levels of *TUSC3* in HCC tissues and the corresponding para-cancerous liver tissues were 0.55±0.34 and 1.07±0.43, respectively (*P*\<0.001). Similarly, qRT-PCR assay revealed that 80% (20/25) of the samples had obviously lower expression, and the relative mRNA expression levels of *TUSC3* in HCC tissues and the matched adjacent tissues were 0.64±0.64 and 1.48±1.17, respectively (*P*\<0.01), as shown in [Figure 3](#f3-ott-11-909){ref-type="fig"}.

Low expression of *TUSC3* in HCC tissues was closely related to Edmondson grade, BCLC stage and tumor size
----------------------------------------------------------------------------------------------------------

Next, we analyzed the correlation between the expression of *TUSC3* and clinicopathological data of HCC. Results indicated that low expression of *TUSC3* in HCC tissues was closely associated with Edmondson grade, BCLC stage and tumor size, and the difference was statistically significant (*P*=0.008, *P*=0.009, *P*=0.020, respectively). However, no statistically significant correlation was found between the *TUSC3* level and age, gender, tumor capsule, vascular invasion, sAFP, HBsAg, cirrhosis, Child-Pugh grading and tumor number, and the difference was not statistically significant (*P*\>0.05) ([Table 1](#t1-ott-11-909){ref-type="table"}). These abovementioned results suggested that the low expression of *TUSC3* might be related to the malignant process of HCC.

Low *TUSC3* levels predicted poor prognosis of patients with HCC
----------------------------------------------------------------

Then we analyzed the relationship between the expression of *TUSC3* and the prognosis of HCC patients by collecting the prognosis data for all patients. The patients in our study were followed up for 2--100 months and the median follow-up time was 25 months. Kaplan--Meier method was performed for survival analysis, and the results showed that patients with lower *TUSC3* expression had a shorter OS time (17 months, 95% confidence interval \[CI\]: 13.010--20.990) than those with higher *TUSC3* expression (36 months, 95% CI: 25.547--46.453; *P*\<0.001). Analogously, the DFS survival curves revealed that the patients with lower *TUSC3* expression had a shorter DFS time when compared with those with higher *TUSC3* expression (9 months, 95% CI: 6.529--11.471 vs 17 months, 95% CI: 10.101--23.899) ([Figure 4](#f4-ott-11-909){ref-type="fig"}). Moreover, univariate analysis indicated that the *TUSC3* expression, Edmondson grade, BCLC stage, tumor capsule, tumor size and vascular invasion were closely correlated with the OS and DFS of HCC patients ([Table 2](#t2-ott-11-909){ref-type="table"}). Multivariate analysis showed that the *TUSC3* level, tumor capsule and vascular invasion were independent risk factors for OS and DFS in postoperative patients with HCC ([Table 3](#t3-ott-11-909){ref-type="table"}).

Discussion
==========

The protein encoded by *TUSC3* is a subunit in the oligosaccharyltransferase (OST) complex that participates in the N-linked glycosylation of the protein folding process.[@b9-ott-11-909],[@b20-ott-11-909] Abnormal expression of *TUSC3* may change the process of N-linked glycosylation, and the abnormity of N-linked glycosylation which participates in biological processes, such as intercellular or cell--matrix communications, plays a crucial role in the occurrence and progression of tumor.[@b21-ott-11-909]--[@b24-ott-11-909] There fore, more and more studies have explored the link between *TUSC3* and malignant tumors. For instance, Horak et al have reported that *TUSC3* expression is significantly associated with promoter hyper-methylation as well as downregulation in advanced prostate cancer patients and indicated that deletion of *TUSC3* in prostate cancer cells may increase the proliferation and invasion of cancer cells. Therefore, *TUSC3* may act as a tumor suppressor gene in prostate cancer.[@b9-ott-11-909] Analogously, it has been reported that the expression of *TUSC3* in ovarian cancer is distinctly decreased due to the methylation of the *TUSC3* promoter region through the study of ovarian cancer cell lines and tumor samples, and the absence of *TUSC3* promotes the proliferation and migration of ovarian cancer cells, which may be related to abnormal N-linked glycosylation.[@b11-ott-11-909],[@b12-ott-11-909] In addition, another study has shown that the expression of *TUSC3* is markedly lower in small-cell lung cancer than that in the normal control, and the low expression of *TUSC3* is associated with poorly differentiated lung cancer.[@b15-ott-11-909] It is also suggested that TUCS3 may be a predictor of lymph node metastasis in patients with lung cancer by analyzing the correlation between *TUSC3* expression and lymph node metastasis.[@b15-ott-11-909] In contrast, there are also studies of the opposite views about the tumorigenic ability of *TUSC3*. For example, Gu et al have found that *TUSC3* is highly expressed in non-small-cell lung cancer and the overexpression of *TUSC3* can enhance cell proliferation, migration and tumor growth ability of human non-small-cell lung cancer cells, which means that *TUSC3* plays a carcinogenic role in non-small-cell lung cancer.[@b14-ott-11-909] Moreover, another study has revealed that *TUSC3* expression is upregulated in colorectal cancer specimens and its overexpression in colorectal cancer cells also increases the abilities of proliferation, migration and tumorigenesis.[@b17-ott-11-909] Based on previous studies, our research has found that *TUSC3* played disparate roles in different tumors. However, the expression and clinical significance of *TUSC3* in HCC remain uncertain.

In this study, through immune-histochemical experiments, we found that the expression of *TUSC3* in HCC was obviously lower than that in the corresponding para-cancerous tissues. Low expression of *TUSC3* in HCC patients was significantly associated with adverse clinical features including Edmondson grade, BCLC stage and tumor size. Furthermore, results of Western blot and qRT-PCR indicated that both the protein and mRNA expression of *TUSC3* were significantly downregulated in HCC tissues, which were consistent with the immune-histochemical results. We hypothesized that downregulation of *TUSC3* in HCC might be related to the methylation of promoter regions; however, the detailed mechanisms need to be further studied. In brief, the above-mentioned results suggested that the expression of *TUSC3* was low in HCC and its downregulation might be associated with HCC growth, invasion and tumor differentiation.

The specific regulatory mechanism of *TUSC3* in tumors is not yet clear. Horak et al have suggested that the loss of *TUSC3* leads to increased N-glycosylation and alleviation of endoplasmic reticulum stress which can enhance the ability of tumorigenesis in prostate cancer cells.[@b9-ott-11-909] They have also reported that *TUSC3* plays an important role in tumor inhibition through distinct regulatory mechanisms including prevention of the epithelial-to-mesenchymal transition and modulation of the endoplasmic reticulum stress response in ovarian cancer cells.[@b10-ott-11-909] Prior studies have found that *TUSC3* promotes autophagy in human non-small-cell lung cancer cells by activating the Wnt/β-catenin signaling pathway, and the tumorigenic role of *TUSC3* in non-small-cell lung cancer may be related to Hedgehog signaling pathway.[@b13-ott-11-909],[@b14-ott-11-909] It has also been reported that *TUSC3* acts as an oncogene in colorectal cancer by inducing epithelial-to-mesenchymal transition and potentially regulating the MAPK, PI3K/Akt and Wnt/β-catenin signaling pathways.[@b17-ott-11-909] Several studies have also demonstrated that *TUSC3* acts as a tumor suppressor in glioblastoma by inhibiting the activity of the Akt signaling pathway, and its role of a target protein is closely related to the formation and progression of glioblastoma.[@b25-ott-11-909]--[@b27-ott-11-909] Based on the abovementioned studies, we can conclude that the regulatory mechanisms of *TUSC3* in tumors may include many aspects. Unfortunately, we failed to elaborate on the molecular mechanism of *TUSC3* in the formation and progression of HCC in this study. We speculated that *TUSC3* played a role of tumor suppressor by regulating endoplasmic reticulum stress response in HCC, and the specific molecular mechanism needs to be further studied as a direction of our further work.

Previous studies have demonstrated the prognostic value of *TUSC3* in other malignancies. Pils et al have observed that *TUSC3* promoter methylation is significantly related to shorter progression-free and OS rates.[@b12-ott-11-909] It has been reported that patients with negative expression of *TUSC3* have obviously shorter OS in esophageal squamous cell carcinoma.[@b28-ott-11-909] Nevertheless, Duppel et al have found that *TUSC3* methylation is markedly associated with a longer OS time in lung cancer.[@b16-ott-11-909] Our results obtained by the Kaplan--Meier method indicated that patients with low expression of *TUSC3* had shorter OS and DFS than those with high expression of *TUSC3*. In addition, we concluded that *TUSC3* was an independent prognostic factor for HCC patients after surgery by using the Cox proportional hazards model.

In summary, we revealed for the first time that the expression of *TUSC3* was downregulated in HCC and its low expression was associated with adverse clinical features and poor OS and DFS in HCC patients. *TUSC3* might play a crucial role in the early diagnosis and prognosis prediction of HCC which was also important in clinical studies. However, the exact molecular mechanisms by which *TUSC3* promotes HCC progression remain unclear and need to be further studied.
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![Representative immunohistochemical staining of *TUSC3* in tumor tissues and matched para-cancerous liver tissues of HCC.\
**Notes:** (**A** and a) Low expression of *TUSC3* in tumor tissues. (**B** and b) High expression of *TUSC3* in tumor tissues. (**C** and c) Low expression of *TUSC3* in para-cancerous liver tissues. (**D** and d) High expression of *TUSC3* in para-cancerous liver tissues. (**A**, **B**, **C**, **D**) Magnification 100×; (a, b, c, d) magnification 400×; scale bar =50 µm.\
**Abbreviations:** *TUSC3*, tumor suppressor candidate 3; HCC, hepatocellular carcinoma.](ott-11-909Fig1){#f1-ott-11-909}

![Western blot analysis of *TUSC3* expression in 25 pairs of HCC tissues and matched adjacent noncancerous tissues.\
**Notes:** (**A**) Representative results of *TUSC3* protein expression in five pairs of HCC tumorous tissues (T) and the matched adjacent noncancerous tissues (N). β-actin served as loading control. (**B**) Statistical analysis of *TUSC3* protein levels by Graph Prism 5.0 software (GraphPad Prism, San Diego, CA, USA) in 25 pairs of HCC tissues and matched adjacent noncancerous tissues (\*\*\**P*\<0.001). The *TUSC3* protein levels were normalized to β-actin.\
**Abbreviations:** *TUSC3*, tumor suppressor candidate 3; HCC, hepatocellular carcinoma.](ott-11-909Fig2){#f2-ott-11-909}

![The statistical analysis of *TUSC3* mRNA levels by Graph Prism 5.0 software (GraphPad Prism, San Diego, CA, USA) in 25 pairs of HCC tissues and matched adjacent noncancerous tissues.\
**Note:** \*\**P*\<0.01.\
**Abbreviations:** *TUSC3*, tumor suppressor candidate 3; HCC, hepatocellular carcinoma.](ott-11-909Fig3){#f3-ott-11-909}

![Kaplan--Meier analysis of OS and DFS curves of HCC patients based on *TUSC3* expression as positive or negative.\
**Notes:** (**A**) Negative expression of *TUSC3* was associated with shorter OS compared with the positive expression of *TUSC3* (n=92; *P*\<0.001; log-rank test). (**B**) Negative expression of *TUSC3* was related to worse DFS compared with the positive expression of *TUSC3* (n=92; *P*\<0.001; log-rank test).\
**Abbreviations:** OS, overall survival; DFS, disease-free survival; *TUSC3*, tumor suppressor candidate 3; HCC, hepatocellular carcinoma.](ott-11-909Fig4){#f4-ott-11-909}

###### 

Relationship between *TUSC3* expression and clinicopathological characteristics of HCC patients (N=92)

  Clinical features   Total   *TUSC3* expression   *χ*^2^ test   *P*-value   
  ------------------- ------- -------------------- ------------- ----------- -------
  Age (years)                                                    0.079       0.779
   ≤50                40      15                   25                        
   \>50               52      21                   31                        
  Gender                                                         0.314       0.576
   Male               79      30                   49                        
   Female             13      6                    7                         
  Tumor size                                                     5.447       0.020
   ≤5 cm              35      19                   16                        
   \>5 cm             57      17                   40                        
  Vascular invasion                                              2.675       0.102
   Absent             34      17                   17                        
   Present            58      19                   39                        
  Tumor capsule                                                  2.296       0.130
   Missing            37      11                   26                        
   Complete           55      25                   30                        
  Edmondson grade                                                10.615      0.001
   I--II              55      29                   26                        
   III--IV            37      7                    30                        
  BCLC stage                                                     6.879       0.009
   A--B               68      32                   36                        
   C--D               24      4                    20                        
  sAFP (ng/mL)                                                   0.028       0.867
   ≤20                47      18                   29                        
   \>20               45      18                   27                        
  HBsAg                                                          0.183       0.669
   Negative           20      7                    13                        
   Positive           72      29                   43                        
  Cirrhosis                                                      0.130       0.719
   Absent             13      4                    9                         
   Present            79      32                   47                        
  Child-Pugh grade                                               1.434       0.231
   A                  70      25                   45                        
   B                  22      11                   11                        
  Tumor number                                                   0.458       0.498
   =1                 68      28                   40                        
   \>1                24      8                    16                        

**Abbreviations:** BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; sAFP, serum alpha-fetoprotein; HBsAg, hepatitis B surface antigen; *TUSC3*, tumor suppressor candidate 3.

###### 

Univariate analysis of variables affecting the OS and DFS of patients with HCC

  Variables                               OS      DFS                                              
  --------------------------------------- ------- -------------- --------- ------- --------------- ---------
  Age (years) (≤50 vs \>50)               1.115   0.710--1.750   0.637     1.308   0.834--2.053    0.243
  Gender (female vs male)                 1.272   0.649--2.493   0.484     1.107   0.581--2.110    0.757
  Tumor size (≤5 cm vs \>5 cm)            3.078   1.863--5.087   \<0.001   3.478   2.055--5.888    \<0.001
  Vascular invasion (absent vs present)   4.926   2.787--8.707   \<0.001   9.097   4.522--18.300   \<0.001
  Tumor capsule (complete vs missing)     2.217   1.377--3.570   0.001     2.070   1.289--3.323    0.003
  Edmondson grade (I--II vs III--IV)      1.931   1.209--3.086   0.006     2.348   1.466--3.761    \<0.001
  BCLC stage (A--B vs C--D)               2.763   1.644--4.643   \<0.001   3.217   1.788--5.788    \<0.001
  sAFP (ng/mL) (≤20 vs \>20)              1.500   0.946--2.379   0.085     1.195   0.757--1.886    0.444
  HBsAg (negative vs positive)            1.370   0.812--2.312   0.239     0.959   0.544--1.690    0.885
  Cirrhosis (absent vs present)           0.862   0.453--1.641   0.650     0.751   0.393--1.435    0.386
  Child-Pugh grade (A vs B)               1.071   0.633--1.811   0.799     1.146   0.686--1.915    0.603
  Tumor number (1 vs \>1)                 1.599   0.964--2.654   0.069     1.623   0.962--2.737    0.069
  *TUSC3* expression (high vs low)        2.832   1.726--4.647   \<0.001   3.142   1.871--5.278    \<0.001

**Abbreviations:** sAFP, serum alpha-fetoprotein; HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; OS, overall survival; DFS, disease-free survival; CI, confidence interval; HR, hazard ratio; BCLC, Barcelona Clinic Liver Cancer; *TUSC3*, tumor suppressor candidate 3.

###### 

Multivariate analysis of variables affecting the OS and DFS of patients with HCC

  Variables                               OS      DFS                                               
  --------------------------------------- ------- --------------- -------- -------- --------------- ---------
  Tumor size (≤5 cm vs \>5 cm)            1.576   0.892--2.783    0.117    1.162    0.585--2.308    0.668
  Vascular invasion (absent vs present)   5.141   2.534--10.427   ,0.001   12.626   5.007--31.840   \<0.001
  Tumor capsule (complete vs missing)     1.948   1.194--3.178    0.008    1.928    1.186--3.137    0.008
  Edmondson grade (I--II vs III--IV)      1.058   0.617--1.813    0.837    1.358    0.770--2.396    0.291
  BCLC stage (A--B vs C--D)               1.244   0.659--2.350    0.501    1.141    0.594--2.194    0.692
  *TUSC3* expression (high vs low)        2.842   1.567--5.153    0.001    3.797    2.073--6.956    \<0.001

**Abbreviations:** OS, overall survival; DFS, disease-free survival; HCC, hepatocellular carcinoma; CI, confidence interval; HR, hazard ratio; BCLC, Barcelona Clinic Liver Cancer; *TUSC3*, tumor suppressor candidate 3.
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